SBK Financial’s Bristol-Myers Squibb BMY Stock Holding History

SBK Financial’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$504K	Hold	7,000	–	–	0.8%	43
2022 Q3	$498K	Hold	7,000	–	–	0.76%	42
2022 Q2	$539K	Hold	7,000	–	–	0.7%	42
2022 Q1	$511K	Hold	7,000	–	–	0.51%	44
2021 Q4	$436K	Buy	+7,000	New	+$411K	0.35%	54

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

SBK Financial's BMY Position: Q4 2022 in Review

SBK Financial held its Bristol-Myers Squibb (BMY) position steady in Q4 2022 at 7,000 shares worth $504K. The position accounts for 0.8% of the portfolio, ranked #43.

SBK Financial first reported a position in BMY in Q4 2021 and has held it in 5 quarters since. The position peaked at $539K in Q2 2022. 2,602 funds tracked by Wall St. Rank hold BMY as of Q4 2022.

SBK Financial held 7,000 shares of Bristol-Myers Squibb worth $504K as of Q4 2022.
SBK Financial left its Bristol-Myers Squibb share count unchanged in Q4 2022.
Bristol-Myers Squibb made up 0.8% of SBK Financial's portfolio in Q4 2022, its #43 holding.
SBK Financial first reported a position in Bristol-Myers Squibb in Q4 2021 and has held it in 5 quarters since.
SBK Financial's Bristol-Myers Squibb position peaked at $539K in Q2 2022.
2,602 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2022.

Based on SBK Financial's 13F filing for Q4 2022, filed 31 Jan 2023.